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Abstract
The classical BCR-ABL-negative Myeloproliferative Neoplasms (MPN) are a group of het-
erogeneous haematological diseases characterized by constitutive JAK-STAT pathway
activation. Targeted therapy with Ruxolitinib, a JAK1/2-specific inhibitor, achieves symp-
tomatic improvement but does not eliminate the neoplastic clone. Similar effects are seen
with histone deacetylase inhibitors (HDACi), albeit with poorer tolerance. Here, we show
that bone marrow (BM) stromal cells (HS-5) protected MPN-derived cell lines (SET-2; HEL
and UKE-1) and MPN patient-derived BM cells from the cytotoxic effects of Ruxolitinib and
the HDACi Vorinostat. This protective effect was mediated, at least in part, by the secretion
of soluble factors from the BM stroma. In addition, it correlated with the activation of signal-
ling pathways important for cellular homeostasis, such as JAK-STAT, PI3K, JNK, MEK-
ERK and NF-κB. Importantly, the pharmacological inhibition of JNK and PI3K pathways
completely abrogated the BM protective effect on MPN cell lines and MPN patient samples.
Our findings shed light on mechanisms of tumour survival and may indicate novel therapeu-
tic approaches for the treatment of MPN.
Introduction
The classical BCR-ABL-negative myeloproliferative neoplasms (MPN) include Polycythaemia
Vera (PV), Essential Thrombocytosis (ET) and Primary Myelofibrosis (PMF). These condi-
tions arise from a clonal defect on myeloid progenitor cells that lead to increased proliferation
of erythroid and megakaryocytic precursors resulting in the excessive production of mature
blood components [1, 2]. The major clinical complications associated with these disorders are
thrombohemorrhagic events, hypercatabolic state, splenomegaly, and transformation to Acute
Myeloid Leukaemia (AML) [3].
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The common mechanism for the three conditions is a dysregulated hyperactivity of the
tyrosine kinase JAK2. The commonest cause of this is a gain of function mutation resulting in
a Valine to Phenilanine substitution at the codon 617 (JAK2V617F) [4–7] leading to the consti-
tutive phosphorylation of this protein with subsequent activation of several downstream signal-
ling pathways like JAK-STAT, MAPK-RAS and PI3K [8]. The JAK2V617Fmutation occurs in
the vast majority of PV patients (up to 97%) and in a large proportion of ET and PMF patients
(50–60%). In addition to this and other JAK2-activating mutations, mutations in genes encod-
ing epigenetic modulators such as TET2, ASXL1, EZH2 and IDH1/2 have been described in
MPN [8–10].
The molecular characterization of MPN has led to the use of JAK and HDAC inhibitors in
these patients [11–15]. Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of PMF
and PV [11, 12, 16, 17]. The treatment of PV and PMF patients with this agent in the context
of clinical trials showed significant improvement in symptoms and splenomegaly but fail to
consistently eradicate the neoplastic clone [11, 12, 17].
Vorinostat (Suberoylanilide Hydroxamic Acid) is an HDAC inhibitor which has been
shown to decrease cellular viability and proliferation of MPN cells in vitro. In mouse models of
MPN, Vorinostat produced haematological responses and, reduced tumour burden [18]. The
same effects were seen in in clinical trials but the tolerability was poor [14]. Other HDAC
inhibitors, like Panobinostat and Givinostat, have produced disappointing results in clinical tri-
als [13, 15].
Leukaemic cells are not isolated entities and interact with the surrounding microenviron-
ment which provides the stimuli which allow neoplastic cells to over-compete their normal
counterparts leading to their growth and progression [19, 20]. The bone marrow (BM) is a spe-
cialized organ where normal haematopoiesis takes place, but it also acts as a sanctuary in which
malignant cells from a variety of haematological disorders thrive, survive and proliferate [21].
The supportive effect of the BM is mediated by the secretion soluble factors, like cytokines, but
also through direct cellular contact between the leukaemic cells and the stromal marrow cells
[20, 22]. In fact, the BM stroma has been implicated in the cytoprotection of leukaemic cells to
a variety of pharmacological compounds [23–26]. In the context of MPN it has been shown
that the BMmicroenvironment protected MPN cells from the cytotoxic action of the JAK
inhibitor Atiprimod [27].
We investigated the protective effect that BM stroma may exert of MPN cells and the mech-
anism by which this effect may be exerted. Our results demonstrate that the incubation of
MPN cells with BM derived stroma impairs the cytotoxic action of both Vorinostat and Ruxoli-
tinib. This effect is achieved by the activation of survival pathways like JNK and PI3K. Impor-
tantly, the pharmacological inhibition of such signalling pathways completely revert the BM
protective effect on MPN cells. These results confirm that the BMmicroenvironment protects
MPN cells from targeted therapies and also provide a potential therapeutic strategy to over-
come this protective effect.
Material and Methods
Primary patient samples and cell lines
MPN patient BM samples were obtained at the Haematology service of the “Instituto Portu-
guês de Oncologia de Lisboa–Francisco Gentil E.P.E.” in the course of routine clinical investi-
gations and following written informed consent. Ethics approval was obtained and all samples
were treated anonymously in accordance with the Declaration of Helsinki. MPN patient char-
acteristics and information (diagnosis; gender; age; presence of JAK2V617Fmutation and in
vitro response to inhibitors) are summarized in Table 1. Mononuclear cells from BM samples
JNK and PI3K Activation Protect MPN Cells
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were separated by density gradient centrifugation and CD34+ cells isolated using Diamond
CD34 isolation kit (Miltenyi Biotec) according to the manufacturer’s instructions. The isolated
cells were cultured in IMDMmedium (Sigma-Aldrich) supplemented with 20% fetal bovine
serum (FBS) (Life Technologies), Antibiotics (Lonza) and L-Glutamine (Life Technologies).
All cell lines were cultured according to standard protocols. The MPN cell lines used in our
study (SET-2, HEL, UKE-1) arbor the JAK2V617Fmutation, both HEL and UKE-1 are homo-
zygous for this mutation, while SET-2 cell line is heterozygous [28]. The MPN cell line HEL
was purchased from ATCC, while SET-2 [29] and UKE-1 [30] were kindly donated by Prof.
Jean Luc-Villeval. The human BM stromal cell lines HS-5 (purchased from ATCC) was kindly
donated by Prof. Paolo Gia and KM-102 by Prof. Motoo Kitagawa [31].
Production of HS-5 conditioned media
HS-5 cells were plated in T75 flasks with 15ml DMEM-10 medium (DMEM supplemented
with 10% FBS, Antibiotics and L-Glutamine) (Life Technologies). Once the cells reached 70%
confluence, the medium was harvested, the cells washed once and 10ml DMEM-10 medium
added to the flasks. The HS-5 conditioned media was collected every 3 days of culture for a
period of 9 days. Following collection, the medium was centrifuged and the supernatant was
stored at -20°C.
In vitro co-culture assays
HS-5 and KM-102 cell lines were cultured to 70% confluence and the MPN cells added to the
stromal layer of HS-5 (+ HS-5) or KM-102 (+ KM-102) at 0.1x106 cells/ml in the appropriate
culture medium, either directly (for cell to cell contact) or indirectly (separated by a 0.4-mm-
thick micropore membranes +HS-5 TW). In addition, MPN cells were incubated without any
stromal support (no stroma) or with the HS-5 conditioned media (+ CM), diluted 50% in the
respective culture media. Vorinostat (Selleckchem), Ruxolitinib (Axon Medchem), SP600125
(JNK inhibitor) (Selleckchem) and LY294002 (PI3K inhibitor) (Cayman Chemicals) were
added to the co-cultures once the MPN cells adhered to the BM stroma. At the indicated time
points the cells were harvested and assessed as described below for viability, gene expression
and immunoblotting.
Table 1. MPN Patient characteristics.
Patient Diagnosis Gender Age at diagnosis JAK2V617F mutation Response to Vorinostat Response to Ruxolitinib
1 AML (Post-PV) F 64 positive ++ ++
2 PV F 60 positive ++ n.d.
3 AML F 55 negative +++ ++
4 ET M 38 negative + +
5 MPN-U M 45 negative + -
6 ET F 72 negative +++ +
7 AML (Post-PV) M 76 positive ++ +
8 MPN-CEL/HES F 23 negative ++ +
9 PV F 52 negative ++ -
AML–Acute Myeloid Leukaemia; PV–Polycythaemia Vera; ET–Essential Thrombocytosis; MPN-U—Myeloproliferative Neoplasm–Unclassified; MPN-CEL/
HES—Myeloproliferative Neoplasm with chronic eosinophilic leukemia/hypereosinophilic syndrome; F–Female; M–Male; n.d.–not determined; Response
to Vorinostat and to Ruxolitinib–these represent the Viability Index (VI) of Lin-CD34+ patients cells treated with Vorinostat and Ruxolitinib without stroma
(- !1.00>VI>0.91; + ! 0.90>VI>0.51; ++ ! 0.50>VI>0.21 and +++ ! 0.20>VI>0.00).
doi:10.1371/journal.pone.0143897.t001
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Cellular viability assays
Harvested cells were stained with CD45-APC (Biolegend), Annexin-V- FITC (Biolegend) and
Propidium Iodide (PI) (Sigma-Aldrich). Flow cytometric data was acquired on a FACSCalibur
flow cytometer (BD Biosciences) and the percentage of viable cells was described as those that
did not stain for Annexin-V nor PI. Viability was also assessed by PI exclusion analysis by
Flow cytometry. The data was analyzed using Flow Jo software version X.0.7 (Tree Star inc.).
Drug titration and interaction analysis
SET-2 cells were cultured alone and with HS-5 cells for 72h and viability analyzed as described
above. Drugs were added to these cultures in the concentrations described in S1 Table, alone
and in the following combinations: Vorinostat (#1) with JNKi-SP600125 (#3); Vorinostat (#1)
with PI3Ki-LY294002 (#4); Ruxolitinib (#2) with JNKi-SP600125 (#3) and Ruxolitinib (#2)
with PI3Ki-LY294002 (#4). The half maximal effective concentration (EC50) calculation was
performed using the GraphPad Prism version 5.00 for Windows (GraphPad Software) and the
drug interactions were calculated using the Chou-Talalay method [32].
RNA extraction, RT-PCR and quantitative Real-Time-PCR
RNA was extracted as described earlier [33], cDNA synthesized and gene expression evaluated
by quantitative Real-Time-PCR (qPCR) and normalized to the expression levels of HPRT1
gene. Primers used for the qPCR are indicated in S2 Table. The reagents were combined
according to standard protocols and the amplifications performed in a LightCycler 480 II ther-
mocycler (Roche).
Immunobloting
Cell lysates were prepared as described [34] and equal amounts of protein were analyzed by
10% SDS-PAGE, transferred onto nitrocellulose membranes, and immunoblotted with the
antibodies described in S3 Table.
Statistical analysis
Differences between populations were calculated using unpaired 2-tailed Student’s t test or
One-way ANOVA, when appropriate using the GraphPad Prism version 5.00 for Windows
(GraphPad Software). A p-value<0.05 was considered significant.
Results
The BMmicroenvironment protects MPN cells from drug-induced
apoptosis
To investigate the protective effect of the BM stroma on MPN cells we used a co-culture
assay where HS-5 cells [35] were incubated with MPN cell lines and primary MPN cells.
Both Vorinostat and Ruxolitinib induced apoptosis of SET-2 cells (Fig 1A and 1B—no stroma
panels), which is in agreement with the reported effects of these agents in MPN cells [18, 36].
Co-culturing SET-2 cells with HS-5 cells (+ HS-5) significantly reduced apoptosis (Fig 1A and
1B—+ HS-5 panels). This protective effect of the HS-5 BM stroma was maintained for up to 6
days of co-culture (S1 Fig).
Despite protecting from apoptosis, co-culturing SET-2 cells with HS-5 did not abrogate the
reported effects that Vorinostat has on gene expression, as shown by the up-regulation of
HDACi transcriptional targets like CDKN1A [34], IER3 [33] and BIRC3 [37] (S2A Fig), nor the
JNK and PI3K Activation Protect MPN Cells
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inhibitory effects of Ruxolitinib on the expression of known JAK-STAT pathway transcrip-
tional targets, such as BCL2 [38], OSM [39] and PIM1 [40] (S2B Fig), which indicates that both
Vorinostat and Ruxolitinib are being effective. Similar protective effects on apoptosis were seen
in the other MPN derived cell lines HEL (S3A Fig) and UKE-1 (S3B Fig). However, unlike pre-
vious descriptions [41] we did not observe apoptosis induced by Ruxolitinib (a JAK1/2 inhibi-
tor) in UKE-1 cells (S3B Fig). Furthermore, co-culture experiments using another BM stromal
cell line (KM-102) [31] confirmed the stromal cells’ protective effect on apoptosis of SET-2
cells induced by Vorinostat (S4A Fig) and Ruxolitinib (S4B Fig). These results demonstrate
that BM stromal cells maintain MPN cellular viability in the presence of both Vorinostat and
Ruxolitinib.
The protective effect of BMmicroenvironment is exerted through
secreted factors
In order to investigate whether the protective effect of BM stromal cells requires direct cell con-
tact (juxtacrine) or is mediated by secreted molecules (paracrine), we cultured SET-2 cells with
the HS-5 conditioned media or with the HS-5 cells without direct contact between stromal and
MPN cells. The conditioned media (+ CM) displayed a similar protective effect from Vorino-
stat (Fig 1A and 1C) and Ruxolitinib (Fig 1B and 1D) -induced apoptosis on SET-2 cells as
direct contact with HS-5 cells (+ HS-5). Likewise, SET-2 cell viability in the presence of Vori-
nostat (Fig 1C) or Ruxolitinib (Fig 1D) was maintained by HS-5 cells even when the two cell
types were cultured in transwell chambers that physically separated them, allowing only the
exchange of soluble factors (+ HS-5 with TW). These results strongly suggest that HS-5 stromal
cells protect MPN cells from apoptosis induced by Vorinostat and Ruxolitinib, at least in part,
by means of soluble factors.
Activation of JNK and PI3K signalling pathways is required for BM
stromal–mediated protection of MPN cells
In order to understand the molecular mechanism by which the HS-5 protects MPN cells from
drug-induced apoptosis, we analyzed the changes in activation of various signalling pathways
induced by the system described above [35]. Signalling pathway activation was measured by
assessing phosphorylation of downstream targets. We co-cultured SET-2 cells in the presence
of a stromal layer of HS-5 cells (+ HS-5) and HS-5 conditioned media (+ CM) for a period of
72h and determined the activation of signalling pathways involved in cellular survival and pro-
liferation by immunoblot analysis. As shown in Fig 2, the presence of HS-5 cells (+ HS-5) or
their conditioned media (+ CM) activated the JAK-STAT, JNK, PI3K, NF-κB and, to a lesser
extent, the MEK-ERK signalling pathways in a time-dependent manner. The kinetics of activa-
tion differed between the signalling pathways analyzed, and the direct contact between the cells
or the presence of HS-5 conditioned media also induced differential activation patterns, as
shown in the P-JNK/SAPK and P-Akt/PKB immunoblots (Fig 2). Interestingly, the activation
of the signalling pathways is accompanied by an induction on the transcript levels of
Fig 1. HS-5 stromal cells protect SET-2 cells from Vorinostat and Ruxolitinib- induced apoptosis. SET-2 cells were cultured in vitro (no stroma) and
co-cultured with a stromal layer of HS-5 cells (+ HS-5), HS-5 conditioned media [+ CM (HS-5)] and or separated by a 0.4-μm-thick micropore membranes
[+ HS-5 (+ TW)]. SET-2 cells were incubated in these conditions for 72h and treated with the indicated concentrations of Vorinostat (A and C) and Ruxolitinib
(B and D). At 72h of co-culture, SET-2 cells were harvested, stained with CD45 (to distinguish between SET-2 and the stromal cell lines) and Annexin-V/PI (A
and B) and PI alone (C and D) to determine cellular viability by Flow Cytometry analysis. The graphs indicate Viability Index that normalizes the viability
values to those of the control conditions (A and C—0.0μMVorinostat and B and D—0nM Ruxolitinib). Values indicate the mean ± standard deviation of the
eight (A and B) and three (C and D) experiments performed (* 0.05>p; ** 0.01>p; *** 0.001>p).
doi:10.1371/journal.pone.0143897.g001
JNK and PI3K Activation Protect MPN Cells
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downstream target genes of the same pathways (data not shown) suggesting robust activation
of these signalling pathways.
We next tested the functional relevance of the observed pathway activation by treating
SET-2 and HS-5 co-cultured cells with Vorinostat or Ruxolitinib in combination with pharma-
cological inhibitors of the pathways found to be activated: MEK/ERK (PD98059); NF-κB
(BMS-345541); PI3K (LY294002) and JNK (SP600125). The co-treatment of SET-2 cells with
Vorinostat or Ruxolinib with the MEK/ERK and NF-κB inhibitors had no impact on the HS-5
BM stroma mediated protection to SET-2 cells (data not shown). However, the treatment com-
bination of either Vorinostat or Ruxolitinib with the JNK or PI3K pharmacological inhibitors
completely reversed the HS-5 BM induced protection of SET-2 cells (Fig 3A and 3B). The
decreased phosphorylation of JNK/SAPK protein following treatment with SP600125 and the
Fig 2. HS-5 stroma activates crucial signalling pathways in SET-2 cells. SET-2 cells were cultured in vitro (no stroma), co-cultured in a stromal layer of
HS-5 cells (+ HS-5) and with HS-5 conditioned media [+ CM (HS-5)] at the indicated time point the cells. Cells were lysed and the phosphorylation and total
levels of STAT5, STAT3, JNK/SAPK, ERK1/2, Akt/PKB, GSK3α/β, S6 and p65/RELA were analyzed by immunoblot. Actin was used as loading control. The
data is representative of two independent experiments.
doi:10.1371/journal.pone.0143897.g002
JNK and PI3K Activation Protect MPN Cells
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decreased phosphorylation of PI3K downstream target GSK3α/β following treatment with
LY294002 (S5 Fig) indicate these drugs are indeed inhibiting these signalling pathways in our
co-culture system.
Combined treatment of Vorinostat and Ruxolitinib with JNK and PI3K
inhibition results in synergistic induction of cell death in MPN cells
Given that the inhibition of both JNK and PI3K signalling pathways completely reversed the
HS-5 BM induced protection of SET-2 cells, we tested whether the combination of the different
pharmacological agents could have synergist effects using the Chou-Talalay method [32]. To
this end, we cultured SET-2 for 72h with or without the HS-5 cells and treated with escalating
concentrations of the combinations of Vorinostat and Ruxolitinib with both SP600125 (JNKi)
and LY294002 (PI3Ki). As shown in S6 Fig, the protective effect of the HS-5 increased the
EC50 of both Vorinostat and Ruxolitinib in SET-2 cells by almost 3 fold (2.19 for Vorinostat
and 2.60 for Ruxolitinib). Combining both SP600125 (JNKi) and LY294002 (PI3Ki) with Vori-
nostat (S6A and S6B Fig) reduced the EC50 (3.30μM to 0.46μM–JNKi and 3.30μM to 1.41μM–
PI3Ki) further demonstrating that the inhibition of these pathways abrogated the protective
effect induced by the HS-5. Furthermore, the combination indexes (CI) of SET-2 cells co-cul-
tured with HS-5 cells and exposed to Vorinostat and SP600125 (JNKi) or LY294002 (PI3Ki)
showed a synergistic effect (CI below 1.00) between the drugs at therapeutically achievable
doses of Vorinostat (X< 2.52μM) [42]. On the other hand, the combination of SP600125
(JNKi) with Ruxolitinib reduced the EC50 (0.26μM to 0.19μM) but not the combination of
LY294002 (PI3Ki) with Ruxolitinib (0.26μM to 0.31μM) (S6C and S6D Fig). However, both
drug combinations induce higher degree of cell death and these effects are synergistic at thera-
peutically achievable doses of Ruxolitinib (X< 1.00μM) [43]. These results further demon-
strate that the HS-5 cells activate JNK and PI3K signalling pathways in SET-2 cells, probably
mediating resistance to apoptosis induced by Vorinostat and Ruxolitinib.
JNK and PI3K signaling pathway activation mediates ex-vivo stromal
protection of primary MPN samples
The above findings were confirmed in primary Lin-CD34+ cells from MPN patients (Table 1),
as with the cell lines, these were co-cultured with HS-5 BM stromal cells in the presence of the
Fig 3. Pharmacological inhibition of JNK and PI3K signalling pathways completely reverted HS-5 BM stromamediated protection of SET-2 cells. (A
and B) SET-2 cells were cultured in vitro (no stroma) and co-cultured in a stromal layer of HS-5 cells (+ HS-5) for 72h in the presence of 2.0μMVorinostat (Vor.),
500nMRuxolitinib (Rux.), 5μMand 10μMSP600125 (JNK inhibitor) (in A) and 5μMand 10μM LY294002 (PI3K inhibitor) (in B). After 72h, the SET-2 cells were
harvested, stained with CD45 (to distinguish between SET-2 and the stromal cell lines) and Annexin-V/PI or PI alone to determine cellular viability by Flow
Cytometry analysis as described in “Materials and Methods”. The panels in (A and B) show the Viability Index graphs that normalize the viability values to those
of the control condition (non-treated condition NT). Values indicate the mean ± standard deviation of the five experiments performed (* 0.05 >p; ** 0.01>p;
*** 0.001>p).
doi:10.1371/journal.pone.0143897.g003
JNK and PI3K Activation Protect MPN Cells
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pharmacological agents. Both Vorinostat (Fig 4A and 4B) and Ruxolitinib (Fig 4C and 4D)
reduced cellular viability, although the degree of reduction varied between patients (Table 1).
Furthermore, co-culture with HS-5 cells significantly protected primary cells from Vorinostat-
(Fig 4A and 4B) and Ruxolitinib- (Fig 4C and 4D) induced apoptosis. Inhibition of JNK (Fig
4A and 4C) and PI3K (Fig 4B and 4D) signalling pathways reversed the protective effect of HS-
5 cells, although the reversion was not as striking as with the cell line model (Fig 3) and was not
seen in all the MPN patient samples (MPN #1; #3 and #6). Nonetheless, the results obtained
with MPN primary samples support our hypothesis that the stroma-mediated protection of
MPN cells from drug-induced apoptosis requires the activation of JNK and PI3K signalling
pathways.
Fig 4. Pharmacological inhibition of JNK and PI3K signalling pathways abrogate the HS-5 BM stroma induced protection of patient derived BM
Lin-CD34+ cells from Vorinostat–induced cytotoxicity. Lin-CD34+ cells were isolated as described in “Material and Methods” section and co-cultured in a
stromal layer of HS-5 cells for 72h in presence of the indicated concentrations of Vorinostat (A and B), Ruxolitinib (C and D) SP600125 (JNKi–A and C) and
LY294002 (PI3Ki–B and D). At 72h of co-culture, cells were harvested, stained with CD45 (to distinguish between Lin-CD34+ and HS-5 cells) and Annexin-V/
PI to determine cellular viability by Flow Cytometry analysis as described in “Materials and Methods”. The results are representative of nine MPN patients
tested and graphics indicate the percentage of viable cells (Annexin-V and PI negative cells) in the indicated conditions (* 0.05 >p; *** 0.001>p).
doi:10.1371/journal.pone.0143897.g004
JNK and PI3K Activation Protect MPN Cells
PLOS ONE | DOI:10.1371/journal.pone.0143897 December 1, 2015 9 / 16
Discussion
The unraveling of the role of JAK2 activation in the molecular pathophysiology of MPN [4–7]
led to the development of JAK2 inhibitors, such as Ruxolitinib. Despite clear efficacy in reduc-
ing disease burden, these agents have failed to eradicate the malignant clone [11, 12]. Similarly,
in light of the identification of epigenetic alterations in MPN, HDAC inhibitors have been
tested in these diseases [13–15]. These yielded modest responses and poor tolerability, but Vor-
inostat was successful in reducing tumour burden in some patients [14]. We postulated that
the BMmicroenvironment could play a role in protecting the MPN cells from the cytotoxic
actions of Ruxolitinib and Vorinostat. There is increasing evidence implicating the BMmicro-
environment in the resistance to therapy in haematological malignancies. Tesfai and colleagues
reported that the BM stroma impaired the response of B-cell Acute Lymphoblatic Leukemia
(B-ALL) cells to cytotoxic agents [23]. In myeloid neoplasms, it was recently reported that tyro-
sine kinase inhibitors are unable to completely eliminate the leukaemic stem cell in Chronic
Myeloid Leukemia cells due to microenvironmental cues [24, 26]. Similarly, a variety of
agents fail to kill Acute Myeloid Leukemia cells [25, 44, 45] in the presence of BM stromal cells.
Here, we demonstrate that the stromal cells protect MPN derived cell lines and primary MPN
Lin- CD34+ cells from apoptosis induced by Vorinostat and Ruxolitinib (Figs 1 and 4).
Several studies indicate that the BM stroma secretes cytokines which protect neoplastic mye-
loid cells from drug-induced apoptosis [24, 25, 27]. Our studies indicate that soluble factors pro-
duced by the stromal cell line HS-5 protected MPN cells from Vorinostat- and Ruxolitinib-
induced apoptosis (Fig 1). Analysis of activation of downstream signalling pathways indicated
that these factors activate several signalling pathways (Fig 2) in MPN cells. We have not yet iden-
tified the secreted factor responsible for this effect but our data indicate that it probably acts
through JNK and PI3K signalling pathway activation. Consistent with this is the preliminary
data from our laboratory suggesting that SCF and GM-CSF could be implicated in the protection
(data not shown). These cytokines are reported to activate MEK-ERK, NF-κB and PI3K signal-
ling pathways [46, 47], and it is tempting to speculate that they might activate these pathways in
our cell-culture system (Fig 2). The activation of JNK signalling pathway by the secreted factors
might occur through IL1β signalling, a cytokine associated with inflammation [48, 49] and also
secreted by HS-5 cells [35]. The identification of the secreted factor(s) responsible for the protec-
tive effect will be important in delineating possible therapeutic targets.
Despite the fact that our data implicate the role of a HS-5 secreted factor in the protective
effect, the importance of the direct contact (or juxtacrine effect) between stromal andMPN cells
cannot be ignored. Higher levels of MPN cellular viability were obtained whenMPN cells were in
direct contact with the HS-5 BM stroma (Fig 1), particularly when treated with Ruxolitinib (Fig
1B). These results might suggest that a combination of juxtacrine and paracrine effects of the HS-
5 BM stroma could contribute to the protection of MPN cells. This is further reinforced by the
fact that adhesion molecules, such as ICAM-1 and E-Cadherin, have been reported to activate
the signalling pathways that we observed in our co-culture system (Fig 2) [50, 51].
In an attempt to improve the efficacy of JAK2 inhibitors, several clinical trials in the MPN
field are testing combinations of Ruxolitinib with drugs which may have synergistic mecha-
nisms of action, such as signalling inhibitors, immunomodulators and epigenetic modulators
[52, 53]. Given our results showing the BM stroma mediated activation of JNK and PI3K sig-
nalling pathways in MPN cells (Fig 2), we tested combinations of Vorinostat and Ruxolitinib
with pharmacological inhibitors of such pathways. In these combinations, JNK (SP600125)
and PI3K (LY294002) inhibitors, abrogated the protective effects of stromal cells on MPN cells
in the cell line model (Fig 3) and also in primary BM-derived Lin-CD34+ MPN cells (Fig 4),
demonstrating that the integrity of these signalling pathways must be maintained in order for
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the HS-5 cells to exert their protective effect. This is supported by the fact that both JNK and
PI3K signalling pathways have been implicated in the regulation of cellular viability in haema-
tological malignancies [54–56]. Furthermore, our results (Figs 3 and 4) are agreement with the
fact that the PI3K signalling pathway has been implicated in the protection of myeloid neoplas-
tic cells to several cytotoxic stimuli [45, 57], suggesting that the PI3K axis may act as a gate-
keeper of the BMmediated protection in myeloid neoplasms. As shown in Fig 4, the level of
reversion of the HS-5-induced protection to Vorinostat and Ruxolitinib with SP600125 and
LY294002 varied among primary MPN cells (MPN patients #1, #3 and #6 failed to revert HS-5
induced protection with SP600125 and LY294002), which might reflect inter-patient variability
and might also suggest that other signalling pathways could be activated in these patients by
stromal cells, such as MEK-ERK or NF-κB (Fig 2). These results suggest the possibility of a
novel therapeutic approach for the treatment of MPN and other haematological malignancies:
the dual targeting of the neoplastic clone (MPN cells) and the microenvironmental cues (stro-
mal-activated signalling pathways). This therapeutic strategy has the potential to overcome
stromal-induced drug resistance and expose the neoplastic stem cells to eradication. Impor-
tantly, the combination of Ruxolitinib and BKM120 (a pan-PI3K inhibitor) is already being
Fig 5. Model for the proposed BMmediated protection of MPN cells. In vitro, MPN cells (SET-2, HEL, UKE-1 cell lines and MPN patient BM-derived
Lin-CD34+ cells) are killed once exposed to chemotherapeutic agents, like Vorinostat and Ruxolitinib, as a result of the inhibition of HDAC enzymes and
JAK2V617F mutant protein kinase, respectively. However, in vivo (in MPN patients) or in the co-culture assays with the HS-5 BM stroma, MPN cells are able
survive the cytotoxic action of these noxious agents through the activation of the JNK and PI3K signalling pathways, allowing MPN cells to escape these
chemotherapeutic regiments and prolonging disease in MPN patients. The mechanisms underlying the activation of these signalling pathways are still
elusive, but we postulate that involves the secretion of soluble factors by the BM stroma and the direct interaction between the MPN cells and the BM
microenvironment.
doi:10.1371/journal.pone.0143897.g005
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tested in a phase I clinical in patients with myelofibrosis (NCT01730248), despite the fact that
the study trial was designed with a different propose.
In summary, we have demonstrated that the BM stroma plays a pivotal role in the protec-
tion of MPN cells from apoptosis induced by Vorinostat and Ruxolitinib. In the absence of
stromal cells and/or their secreted factors, Vorinostat and Ruxolitinib lead to MPN cell death.
However, when MPN cells are placed in contact with BM stromal cells, this leads to the activa-
tion of JNK and the PI3K signalling pathways which protect MPN cells from Vorinostat and
Ruxolitinib induced apoptosis (Fig 5). Inhibition of these pathways in the same system abro-
gates the protective effect exerted by the stroma. These results point to a novel potential thera-
peutic approach to treat MPN patients: the dual targeting of both the neoplastic clone and the
microenvironmental cues.
Supporting Information
S1 Fig. HS-5 stromal cells protect MPN cells from Vorinostat and Ruxolitinib- induced
apoptosis in a time-dependent manner. SET-2 cells were cultured in vitro (no stroma) and co-
cultured with a stromal layer of HS-5 cells (+ HS-5) up to 144h and treated with the indicated
concentrations of Vorinostat (A) and Ruxolitinib (B). At the indicated time points, SET-2 cells
were harvested, stained with CD45 (to distinguish between SET-2 and the stromal cell lines) and
Annexin-V/PI or PI alone to determine cellular viability by Flow Cytometry analysis as described
in the “Material andMethods” section. The panels show the Viability Index graphs that normal-
ize the viability values to those of the 0h time point. Values indicate the mean ± standard devia-
tion of the three experiments performed ( 0.05>p;  0.01>p;  0.001> p).
(TIF)
S2 Fig. Vorinostat and Ruxolitinib modulate expression of HDAC and JAK-STAT path-
ways responsive genes. SET-2 cells were cultured in vitro (no stroma) and co-cultured in a
stromal layer of HS-5 cells (+ HS-5) for 24h in the presence of 2.0μMVorinostat (A) and
500nM Ruxolitinib (B). The transcript levels of the indicated genes (A–CDKN1A; IER3 and
BIRC3 / B–BCL2; OSM and PIM1) were evaluated as described in the “Material and Methods”
section. The values of each gene were normalized to HPRT1 and depicted as relative values of
the control condition (no stroma–A—0.0μMVorinostat and B – 0nM Ruxolitinib). Values
indicate the mean ± standard deviation of duplicates ( 0.05>p;  0.01>p;  0.001>p).
(TIF)
S3 Fig. HS-5 stromal cells protect MPN cells from Vorinostat and Ruxolitinib- induced
apoptosis. HEL (A) and UKE-1 (B) cells were cultured in vitro (no stroma) and co-cultured
with a stromal layer of HS-5 cells (+ HS-5) for 72h and incubated with the indicated concentra-
tions of Vorinostat and Ruxolitinib. At 72h of co-culture, HEL and UKE-1 cells were harvested,
stained with CD45 (to distinguish between MPN cells and the HS-5 stromal cell line) and
Annexin-V/PI or PI alone to determine cellular viability by Flow Cytometry analysis as
described in the “Material and Methods” section. The panels show the Viability Index graphs
that normalize the viability values to the viability values of the control conditions (0.0μMVori-
nostat and 0.0μMRuxolitinib). Values indicate the mean ± standard deviation of triplicates (A)
and quadriplicates (B) ( 0.05>p;  0.01>p;  0.001>p).
(TIF)
S4 Fig. HS-5 and KM-102 stromal cells protect SET-2 cells from Vorinostat and Ruxoliti-
nib- induced apoptosis. SET-2 cells were cultured in vitro (no stroma) and co-cultured with a
stromal layer of HS-5 cells (+ HS-5) and KM-102 cells (+ KM-102) for 72h and incubated
with the indicated concentrations of Vorinostat (A) and Ruxolitinib (B). At 72h of co-culture,
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SET-2 cells were harvested, stained with CD45 (to distinguish between SET-2 and the stromal
cell lines) and Annexin-V/PI or PI alone to determine cellular viability by Flow Cytometry
analysis as described in the “Material and Methods” section. The A and B panels show the Via-
bility Index graphs that normalize the viability values to the viability values of the control con-
ditions (A—0.0μMVorinostat and B—0nM Ruxolitinib). Values indicate the mean ± standard
deviation of triplicates ( 0.05>p;  0.01>p;  0.001>p).
(TIF)
S5 Fig. Pharmacological inhibition of JNK and PI3K decreases phosphorylation of down-
stream modulators of signalling pathways. SET-2 cells were cultured in vitro (no stroma), co-
cultured in a stromal layer of HS-5 cells (+ HS-5) and with HS-5 conditioned media [+ CM
(HS-5)] with or without 10μM SP600125 and 10μM LY294002 for 24h. Cells were lysed and
the phosphorylation and total levels of STAT5, STAT3, JNK/SAPK and GSK3α/β were ana-
lyzed by immunoblot. Actin was used as loading control. The data is representative of two
independent experiments.
(TIF)
S6 Fig. Pharmacological inhibition of JNK and PI3K synergistically interacts with Vorino-
stat and Ruxolitinib to revert HS-5 stroma mediated protection of SET-2 cells. SET-2 cells
were cultured in vitro (no stroma) and co-cultured in a stromal layer of HS-5 cells (+ HS-5) for
72h with increasing concentrations of Vorinostat (A and B) and Ruxolitinib (C and D) (10 con-
centrations ranging from 0.0 to 8.0μM) that were combined with increasing doses of SP600125
(A and C) and LY294002 (B and D) (10 concentrations ranging from 0.0 to 80μM). At 72h of
co-culture, SET-2 cells were harvested, stained with CD45 (to distinguish between SET-2 and
the stromal cell lines) and PI to determine cellular viability by Flow Cytometry analysis as
described in the “Material and Methods” section. The graphs in the panels show the dose
response curves of the drugs in the following conditions: no stroma; + HS-5 and + HS-5 +
Drug (SP or LY). The EC50 and the Combination Indexes for each of the drug combinations
are show and were calculated as described in “Materials and Methods” section. The data is rep-
resentative of three independent experiments.
(TIF)
S1 Table. Drug concentrations used to calculated EC50 and drug interaction.
(DOCX)
S2 Table. Primers used in the quantitative-RealTime-PCR (qPCR).
(DOCX)
S3 Table. Antibodies used in the Immunoblotting.
(DOCX)
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